Catalysts / CMPX
Upcoming FDA decisions and readouts we track for Compass Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Compass Therapeutics (CMPX, listed on Nasdaq). They cover 3 programmes: Tovecimig (Biliary tract cancer (DLL4 x VEGF-A bispecific)), CTX-8371 (TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1)) and CTX-10726 (Solid tumours (PD-1 x VEGF-A bispecific)).
First on the list: the Phase 2/3 readout for Tovecimig (Biliary tract cancer (DLL4 x VEGF-A bispecific)), guided by the company to Oct 2026. The furthest-out event tracked is Q4 2026. By stage, the upcoming rows are 2 Phase 1 readouts and 1 Phase 2/3 readout.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout; Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Compass Therapeutics CMPX · Nasdaq | Tovecimig | Biliary tract cancer (DLL4 x VEGF-A bispecific) | Oct 2026 company guidance |
Phase 2/3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Compass Therapeutics CMPX · Nasdaq | CTX-8371 | TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1) | Q4 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Compass Therapeutics CMPX · Nasdaq | CTX-10726 | Solid tumours (PD-1 x VEGF-A bispecific) | Q4 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList